EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the European Society of Medical Oncology-Magnitude of Clinical Benefit Scale Version 1.1 for the Treatment of Extracranial Oligometastatic Non-Small Cell Lung Cancer With Radiosurgery

James B Yu, Benjamin W Corn, Summer S Qureshi, Vikram Jairam, Lucy M Yu, Praveen Pendyala, Adeel Riaz, Ronald D Ennis, Eli Sapir

Practical Radiation Oncology · 2026

DOI: 10.1016/j.prro.2025.07.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Practical Radiation Oncology, 2026. Verfasst von James B Yu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire; Cancer Outcomes, Public Policy, and Effectiveness Resea…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Radiosurgery, Lung Neoplasms. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The European Society of Medical Oncology (ESMO) magnitude of clinical benefit scale (MCBS) version 1.1 is an evaluation scale that was developed to evaluate the MCBS reported in clinical research studies of cancer treatments. The American Society for Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) created joint guidelines for the use of local therapy in the management of extracranial oligometastatic non-small cell lung cancer (NSCLC). We applied the ESMO-MCBS v.1.1 to evaluate the clinical benefit reported in studies that informed the ASTRO/ESTRO guidelines. METHODS AND MATERIALS: We applied the ESMO-MCBS v1.1 to the 23 studies identified by the ASTRO/ESTRO taskforce. As well, we evaluated the recently published Consolidative Use of Radiotherapy to Block Oligoprogression study and Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer Trial, for a total of 25 studies evaluated. All evaluated studies were graded by at least 3 of the authors. Any discrepancies were subsequently reviewed by the scoring authors. RESULTS: The addition of stereotactic body radiation therapy to all sites of oligometastatic disease in combination with standard-of-care chemotherapy was associated with substantial improvements in survival. These studies resulted in a score of 4 using form 2a (noncurative treatment with overall survival from standard therapy between 12 and 24 months). Of the 10 prospective single-arm studies, 9 received a score of 3 using form 3, due to progression-free survival exceeding 6 months. No studies received a score of 5 (highest clinical benefit). CONCLUSIONS: The use of local radiation in the treatment of extracranial oligometastatic NSCLC is associated with a substantial clinical benefit, according to the ESMO-MCBS v1.1. Radiation therapy was comparable to established and groundbreaking targeted therapies such as pembrolizumab in combination with pemetrexed for epidermal growth factor receptor and anaplastic lymphoma kinase-negative NSCLC, and osimertinib for epidermal growth factor receptor-mutated NSCLC. MCBS would be even higher if quality-of-life improvements are found in future trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungRadiosurgeryLung NeoplasmsHumansSocieties, MedicalEurope

Autor:innen und Institutionen

  • Department of Radiation Oncology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire; Cancer Outcomes, Public Policy, and Effectiveness Research Center at Yale, New Haven, Connecticut. Electronic address: james.…
  • Department of Radiation Oncology, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
  • Department of Radiation Oncology, Sutter Health, Auburn, California.
  • Department of Radiation Oncology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
  • Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio.

Zitieren

APA

Yu, J. B., Corn, B. W., Qureshi, S. S., Jairam, V., Yu, L. M., Pendyala, P., Riaz, A., Ennis, R. D., & Sapir, E. (2026). Evaluation of the European Society of Medical Oncology-Magnitude of Clinical Benefit Scale Version 1.1 for the Treatment of Extracranial Oligometastatic Non-Small Cell Lung Cancer With Radiosurgery. Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2025.07.008

Vancouver

Yu JB, Corn BW, Qureshi SS, Jairam V, Yu LM, Pendyala P, et al. Evaluation of the European Society of Medical Oncology-Magnitude of Clinical Benefit Scale Version 1.1 for the Treatment of Extracranial Oligometastatic Non-Small Cell Lung Cancer With Radiosurgery. Practical Radiation Oncology. 2026. doi:10.1016/j.prro.2025.07.008

BibTeX
@article{Yu2026,
  author = {Yu, James B and Corn, Benjamin W and Qureshi, Summer S and Jairam, Vikram and Yu, Lucy M and Pendyala, Praveen and Riaz, Adeel and Ennis, Ronald D and Sapir, Eli},
  title = {Evaluation of the European Society of Medical Oncology-Magnitude of Clinical Benefit Scale Version 1.1 for the Treatment of Extracranial Oligometastatic Non-Small Cell Lung Cancer With Radiosurgery},
  journal = {Practical Radiation Oncology},
  year = {2026},
  doi = {10.1016/j.prro.2025.07.008}
}
Kostenlos starten →